Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 15/20 | 0.49 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765220 | 0.93 | PPARG (0.46) | PPARGPPARARARGRXRAKDM4E | |
| SCHEMBL1415411 | 0.88 | PPARG (0.44) | PPARGPPARARARGRXRALTA4H | |
| SCHEMBL602342 | 0.84 | PPARG (0.67) | PPARGPPARARARGRXRAKDM4E | |
| SCHEMBL1415588 | 0.83 | PPARG (0.43) | PPARGPPARARARGRXRALTA4H | |
| SCHEMBL6606406 | 0.83 | PPARG (0.66) | PPARGPPARARARGRXRAKDM4E | |
| Hydrochloric Acid SCHEMBL28341874 | 0.83 | PPARG (0.66) | PPARGPPARARARGRXRAKDM4E | |
| SCHEMBL9325005 | 0.82 | PPARG (0.48) | PPARGPPARARARGRXRALTA4H | |
| SCHEMBL1415555 | 0.80 | PPARG (0.42) | PPARGPPARARARGRXRAHRH3 | |
| SCHEMBL1415517 | 0.80 | PPARG (0.42) | PPARGPPARARARGRXRAALDH1A1 | |
| SCHEMBL1415361 | 0.80 | PPARG (0.42) | PPARGPPARARARGRXRAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6787551-B2 | ORAL ADMINISTRATION; TREATING INSULIN RESISTANCE USING A NEW MECHANISM TO LOWER BLOOD SUGAR LEVEL BY INCREASING PHYSIOLOG-ICAL EFFECTS OF INSULIN ON TARGET CELLS (MUSCLE, ADIPOCYTES, LIVER); ALSO STRONGER ANTILIPIDEMIC THAN ROSIGLITAZONE | CHONG KUN DANG PHARMACEUTICAL CORPORATION (KR) | 2004-09-07 | — | — | US | claimed |